These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 32610185)

  • 1. The MyD88 inhibitor TJ-M2010-2 suppresses proliferation, migration and invasion of breast cancer cells by regulating MyD88/GSK-3β and MyD88/NF-κB signalling pathways.
    Liu JH; Chen C; Li ZY; Zou ZM; Gao DC; Zhang X; Kuang XW; Sun ZH; Zheng WJ; Zhou P; Sun SR
    Exp Cell Res; 2020 Sep; 394(2):112157. PubMed ID: 32610185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of MyD88 Homodimerization by Novel Synthetic Inhibitor TJ-M2010-5 in Preventing Colitis-Associated Colorectal Cancer.
    Xie L; Jiang FC; Zhang LM; He WT; Liu JH; Li MQ; Zhang X; Xing S; Guo H; Zhou P
    J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26712311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Inhibitor of Homodimerization Targeting MyD88 Ameliorates Renal Interstitial Fibrosis by Counteracting TGF-β1-Induced EMT in Vivo and in Vitro.
    Liu JH; He L; Zou ZM; Ding ZC; Zhang X; Wang H; Zhou P; Xie L; Xing S; Yi CZ
    Kidney Blood Press Res; 2018; 43(5):1677-1687. PubMed ID: 30380557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TJ-M2010-5, A self-developed MyD88 inhibitor, attenuates liver fibrosis by inhibiting the NF-κB pathway.
    Xie Y; Du D; Zhang L; Yang Y; Zou Z; Li Z; Zhou L; Shang R; Zhou P
    Chem Biol Interact; 2022 Feb; 354():109839. PubMed ID: 35101388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term use of MyD88 inhibitor TJ-M2010-5 prevents d-galactosamine/lipopolysaccharide-induced acute liver injury in mice.
    Ding Z; Du D; Yang Y; Yang M; Miao Y; Zou Z; Zhang X; Li Z; Zhang X; Zhang L; Wang X; Zhao Y; Jiang J; Jiang F; Zhou P
    Int Immunopharmacol; 2019 Feb; 67():356-365. PubMed ID: 30583234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological inhibition of MyD88 homodimerization counteracts renal ischemia reperfusion-induced progressive renal injury in vivo and in vitro.
    Zhang LM; Liu JH; Xue CB; Li MQ; Xing S; Zhang X; He WT; Jiang FC; Lu X; Zhou P
    Sci Rep; 2016 Jun; 6():26954. PubMed ID: 27246399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TJ-M2010-5, a novel MyD88 inhibitor, corrects R848-induced lupus-like immune disorders of B cells in vitro.
    Zou Z; Du D; Miao Y; Yang Y; Xie Y; Li Z; Zhou L; Zhang L; Zhou P; Jiang F
    Int Immunopharmacol; 2020 Aug; 85():106648. PubMed ID: 32504998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-EMT properties of CoQ0 attributed to PI3K/AKT/NFKB/MMP-9 signaling pathway through ROS-mediated apoptosis.
    Yang HL; Thiyagarajan V; Shen PC; Mathew DC; Lin KY; Liao JW; Hseu YC
    J Exp Clin Cancer Res; 2019 May; 38(1):186. PubMed ID: 31068208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term Pharmacological Inhibition of MyD88 Homodimerization by a Novel Inhibitor Promotes Robust Allograft Tolerance in Mouse Cardiac and Skin Transplantation.
    Li C; Zhang LM; Zhang X; Huang X; Liu Y; Li MQ; Xing S; Yang T; Xie L; Jiang FC; Jiang HY; He WT; Zhou P
    Transplantation; 2017 Feb; 101(2):284-293. PubMed ID: 27607533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disulfiram inhibits TGF-β-induced epithelial-mesenchymal transition and stem-like features in breast cancer via ERK/NF-κB/Snail pathway.
    Han D; Wu G; Chang C; Zhu F; Xiao Y; Li Q; Zhang T; Zhang L
    Oncotarget; 2015 Dec; 6(38):40907-19. PubMed ID: 26517513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MCP-1-induced ERK/GSK-3β/Snail signaling facilitates the epithelial-mesenchymal transition and promotes the migration of MCF-7 human breast carcinoma cells.
    Li S; Lu J; Chen Y; Xiong N; Li L; Zhang J; Yang H; Wu C; Zeng H; Liu Y
    Cell Mol Immunol; 2017 Jul; 14(7):621-630. PubMed ID: 26996066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGF/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-κB and β-catenin.
    Luo M; Hou L; Li J; Shao S; Huang S; Meng D; Liu L; Feng L; Xia P; Qin T; Zhao X
    Cancer Lett; 2016 Apr; 373(1):1-11. PubMed ID: 26805761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ponicidin inhibits pro-inflammatory cytokine TNF-α-induced epithelial-mesenchymal transition and metastasis of colorectal cancer cells via suppressing the AKT/GSK-3β/Snail pathway.
    Zhang Z; Xu J; Liu B; Chen F; Li J; Liu Y; Zhu J; Shen C
    Inflammopharmacology; 2019 Jun; 27(3):627-638. PubMed ID: 30244296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond knockout: A novel homodimerization-targeting MyD88 inhibitor prevents and cures type 1 diabetes in NOD mice.
    Zhang X; Xing S; Li M; Zhang L; Xie L; He W; Liu J; Chang S; Jiang F; Zhou P
    Metabolism; 2016 Sep; 65(9):1267-77. PubMed ID: 27506734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Micafungin exerts antitumor effect on breast cancer and osteosarcoma through preventing EMT in tumor cells in an USP7/AKT/GSK-3β pathway-dependent manner.
    Wang QL; Wang L; Li QY; Li HY; Lin L; Wei D; Xu JY; Luo XJ
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):4447-4459. PubMed ID: 38108838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo.
    Srivastava RK; Kurzrock R; Shankar S
    Mol Cancer Ther; 2010 Dec; 9(12):3254-66. PubMed ID: 21041383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disulfiram combined with copper inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma through the NF-κB and TGF-β pathways.
    Li Y; Wang LH; Zhang HT; Wang YT; Liu S; Zhou WL; Yuan XZ; Li TY; Wu CF; Yang JY
    J Cell Mol Med; 2018 Jan; 22(1):439-451. PubMed ID: 29148232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells.
    Wang L; Hu D; Xie B; Xie L
    Invest New Drugs; 2022 Jun; 40(3):506-518. PubMed ID: 35089465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulating the conformation of the TIR domain by a neoteric MyD88 inhibitor leads to the separation of GVHD from GVT.
    Xing S; Zhang X; Huang X; Xie L; Jiang F; Zhou P
    Leuk Lymphoma; 2019 Jun; 60(6):1528-1539. PubMed ID: 30501537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implication of myeloid differentiation factor 88 inhibitor TJ-M2010-5 for therapeutic intervention of hepatocellular carcinoma.
    Liu J; Zhang X; Wang H; Zhang M; Peng Y; Li M; Xie L; Jiang F; Gong Y; Zhao Q; Zhou P
    Hepatol Res; 2019 Oct; 49(10):1182-1194. PubMed ID: 31074165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.